| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PYCR2 |
| Uniprot No | Q96C36 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-320aa |
| 氨基酸序列 | SVGFIGAGQ LAYALARGFT AAGILSAHKI IASSPEMNLP TVSALRKMGV NLTRSNKETV KHSDVLFLAV KPHIIPFILD EIGADVQARH IVVSCAAGVT ISSVEKKLMA FQPAPKVIRC MTNTPVVVQE GATVYATGTH ALVEDGQLLE QLMSSVGFCT EVEEDLIDAV TGLSGSGPAY AFMALDALAD GGVKMGLPRR LAIQLGAQAL LGAAKMLLDS EQHPCQLKDN VCSPGGATIH ALHFLESGGF RSLLINAVEA SCIRTRELQS MADQEKISPA ALKKTLLDRV KLESPTVSTL TPSSPGKLLT RSLALGGKKD |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与PYCR2重组蛋白相关的文献示例(内容为虚构，供参考)：
1. **文献名称**：*Structural Insights into PYCR2 Function in Proline Biosynthesis*
**作者**：Zhang L. et al.
**摘要**：解析PYCR2重组蛋白的晶体结构，揭示其催化底物结合位点及与PYCR1的构象差异，为靶向PYCR2的抑制剂设计提供结构基础。
2. **文献名称**：*PYCR2 Knockdown Impairs Mitochondrial Function and Promotes Oxidative Stress*
**作者**：Smith J. et al.
**摘要**：通过重组PYCR2蛋白回补实验，证明PYCR2缺失导致线粒体膜电位下降和活性氧累积，提示其在维持细胞氧化还原平衡中的关键作用。
3. **文献名称**：*PYCR2 Overexpression Correlates with Tumor Progression in Glioblastoma*
**作者**：Wang Y. et al.
**摘要**：利用重组PYCR2蛋白进行体外肿瘤细胞模型研究，发现其通过调控脯氨酸代谢促进胶质母细胞瘤侵袭，提示PYCR2为潜在治疗靶点。
4. **文献名称**：*Functional Characterization of PYCR2 Mutants Linked to Neurodegeneration*
**作者**：Garcia R. et al.
**摘要**：通过重组突变体PYCR2蛋白的酶活分析，揭示某些遗传突变导致催化功能丧失，可能与早发性神经退行性疾病相关。
(注：以上文献为示例，实际研究中需查阅真实数据库如PubMed获取准确信息。)
**Background of PYCR2 Recombinant Protein**
PYCR2 (pyrroline-5-carboxylate reductase 2) is a mitochondrial enzyme encoded by the *PYCR2* gene, belonging to the PYCR family of reductases. It plays a critical role in the proline biosynthesis pathway by catalyzing the final step—the NAD(P)H-dependent reduction of pyrroline-5-carboxylate (P5C) to proline. This reaction is essential for maintaining cellular proline levels, which contribute to protein synthesis, redox balance, and stress adaptation. PYCR2 is particularly vital in tissues with high metabolic demands, such as the brain, where proline supports neuronal function and mitochondrial integrity.
Dysregulation of PYCR2 has been linked to neurodevelopmental and neurodegenerative disorders. Mutations in *PYCR2* are associated with autosomal recessive hypomyelinating leukodystrophy-10 (HLD10), characterized by progressive neurological decline, intellectual disability, and hypomyelination. Studies suggest that PYCR2 deficiency disrupts mitochondrial metabolism, leading to impaired proline homeostasis, oxidative stress, and compromised cellular resilience.
Recombinant PYCR2 protein is engineered via heterologous expression systems (e.g., *E. coli* or mammalian cells) to produce purified, functional enzyme for research. It enables mechanistic studies of proline metabolism, disease modeling, and drug screening. Researchers use it to investigate PYCR2’s structure-function relationships, substrate specificity, and interactions with cofactors like NAD(P)H. Additionally, recombinant PYCR2 aids in exploring therapeutic strategies for PYCR2-related disorders, such as small-molecule activators or gene therapy approaches.
Overall, PYCR2 recombinant protein serves as a pivotal tool for unraveling the enzyme’s biological roles and developing interventions for metabolic and neurological diseases linked to proline biosynthesis defects.
×
